Compare Cytokinetics Inc (CYTK) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs KLA Corp. — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while KLA Corp. trades at $201.2 (market cap $256.86B). The key difference: KLA Corp. is far larger — about 29.8× Cytokinetics Inc's market cap, and KLA Corp. pays a 0.47% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and KLA Corp. for 60 Days on average.
| CYTK | KLAC | |
|---|---|---|
Market Cap | $8.62B | $256.86B |
Volume | 2,594,626 | 7,016,455 |
Sector | Health | Technology |
52-Week High | $87.26 | $301.71 |
52-Week Low | $54.76 | $98.28 |
Typical Hold Time | 19 Days | 60 Days |
Enterprise Value | $8.72B | $258.11B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
KLA Corporation (KLAC) trades at $196.83, down 0.32% on the day, with strong technical momentum indicated by bullish moving averages. The company shows robust fundamentals with Q2 2026 EPS beating expectations at $1.05 versus $1.00 estimate, and maintains impressive profitability metrics including 35.57% net income margin and 87.5% ROE. Recent news highlights AI-driven demand boosting KLA's $12.57 billion backlog and positioning the company for continued growth in semiconductor equipment markets.
KLA presents a compelling investment case with analyst consensus price target of $223.88 representing 14% upside potential. The stock benefits from strong AI infrastructure spending and dominant market position in semiconductor inspection equipment. Key risks include competitive pressures from Applied Materials and ASML, valuation multiples above industry averages, and potential margin compression from increased R&D spending. Institutional ownership remains strong with recent acquisitions by Envestnet Portfolio Solutions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
